• / Free eNewsletters & Magazine
  • / My Account
Home>IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

09/28/2017

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (Nasdaq: ICPT). Investors who purchased or otherwise acquired shares between May 31, 2016, and September 20, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the November 27, 2017 lead plaintiff motion deadline.

If you purchased Intercept shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Intercept made materially false and/or misleading statements and/or failed to disclose that its lead product candidate, Ocaliva, entailed undisclosed safety risks, including death, to patients suffering from primary biliary cholangitis (“PBC”). As a result, the Company’s public statements were materially false and misleading at all relevant times. On September 12, 2017, Intercept issued a letter that warned physicians against overdosing patients with Ocaliva, advising them that the drug has been connected to liver injuries and death among patients suffering from PBC. On September 21, 2017, the U.S. Food & Drug Administration issued a safety announcement entitled “FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva for rare chronic liver disease,” warning doctors after reports of multiple deaths linked to the drug. When this news was announced, shares of Intercept declined in value materially, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esquire, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

©2017 Morningstar Advisor. All right reserved.